Skip to main content
Elsevier

Journals in Oncology

Focusing on tumor biology, diagnostics, and targeted therapies, this portfolio supports oncologists, researchers, and clinicians. It features innovations that improve cancer detection, personalized treatments, and survivorship care.

  • Clinical Lymphoma, Myeloma & Leukemia

    • ISSN: 2152-2650
    Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
    Subscriptions

  • Trends in Cancer

    • ISSN: 2405-8033
    Trends in Cancer is a new member of the Trends review journals, offering concise and engaging expert commentary articles that address key frontline research topics and cutting-edge advances in the rapidly changing field of cancer discovery and medicine. The journal provides a unique platform for multidisciplinary information, discussion and education that is valuable for scientists, clinicians, and policy makers, as well as patients and advocates. The latest opportunities, challenges and potential impact of basic, translational and clinical findings, industry R&D, technology and innovation, ethics, or cancer policy and funding are equally presented and debated in an authoritative but reader-friendly format.Critical issues to be covered in the journal include: Adult and Pediatric Cancers; Personalized Medicine; Tumor Microenvironment, Resistance and Metastasis; Immunotherapy; Metabolism; Genetics and Epigenetics; Diagnostics, Biomarkers and Treatment; Epidemiology and Cancer Prevention; Cancer related Ethics, Policy and Funding Initiatives.Visit the Cell Press website for more information about Trends in Cancer - http://www.cell.com/...
    Subscriptions

  • The Lancet Haematology

    • ISSN: 2352-3026
    The Lancet Haematology is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. The journal publishes original research, review, and opinion covering international issues, providing a clear, independent perspective about the clinical advances and practice-changing research shaping clinical haematology.The Lancet Haematology is dedicated to publishing original research that advocates change in, or illuminates, haematological clinical practice, including, but not limited to, the subjects of: haematology-oncology... red and white blood cell disorders, platelet disorders, stem cell transplantation and induced pluripotent stem cells, and transfusion medicine.
    Subscriptions

  • Cancer Treatment Reviews

    • ISSN: 0305-7372
    Cancer Treatment Reviews is an international journal that provides state of the art, authoritative review articles to the clinician and researcher to keep them abreast of modern concepts and the latest developments in cancer treatment research.Journal of Cancer Treatment Reviews' Inclusion and Diversity PledgeThis journal pledges to maintain diversity on the editorial team. This sits within Elsevier's broader ongoing inclusion & diversity efforts. Equity and inclusion in publishing is critically important for scientific excellence and innovation. We believe passionately in the power of an inclusive publishing environment, not only to do what is right, but to enrich, strengthen and advance us all.
    Subscriptions

  • Mutation Research: Genetic Toxicology and Environmental Mutagenesis

    • ISSN: 1383-5718
    A section of Mutation ResearchMutation Research: Genetic Toxicology and Environmental Mutagenesis (MRGTEM) publishes papers advancing knowledge in the field of genetic toxicology. Papers are welcomed in the following areas:New developments in genotoxicity testing of chemical agents (e.g., in methodology of assay systems and interpretation of results).Alternative... to and refinement of the use of animals in genotoxicity testing.Nano-genotox... the study of genotoxicity hazards and risks related to novel man-made nanomaterials.Studie... of epigenetic changes in relation to genotoxic effects.The use of structure-activity relationships in predicting genotoxic effects.The isolation and chemical characterization of novel environmental mutagens.The measurement of genotoxic effects in human populations, when accompanied by quantitative measurements of environmental or occupational exposures.The application of novel technologies for assessing the hazard and risks associated with genotoxic substances (e.g., OMICS or other high-throughput approaches to genotoxicity testing).Telomere biology as an endpoint for examination of the effects of chemicals and other environmental exposures.Extracts and complex mixturesAny submissions that report the results of studies on extracts or complex mixtures (e.g., solvent extracts of herbal preparations; soil, air, or water samples) will receive preliminary review by an Editor. Unless such manuscripts offer significant new insight, such as the chemical identification of previously unknown mutagens or anti-mutagens, they will be returned to the authors without being sent for further review. For further clarification of this journal policy please refer to the Editorial published in Mutation Research 391 (1997) 1.MRGTEM is now accepting submissions for a new section of the journal, "Current Topics in Genotoxicity Testing," that will be dedicated to the discussion of current issues relating to design, interpretation, and strategic use of genotoxicity tests. This section is envisaged to include discussions relating to the development of new international testing guidelines, but also to wider topics in the field. The evaluation of contrasting or opposing viewpoints is welcomed as long as the presentation is in accordance with the journal’s aims, scope, and policies.MRGTEM supports and follows the general direction proposed by all major societies in the field part of the International Association of Environmental Mutagenesis and Genomics Societies (IAEMGS):Asociacion Latinoamericana de Mutagenesis, Carcinogenesis y Teratogenesis Ambiental (ALAMCTA)Brazilian Association of Mutagenesis and Environmental Genomics (MutaGen-Brasil)Chin... Environmental Mutagen Society (CEMS)European Environmental Mutagenesis and Genomics Society (EEMGS)Environmental Mutagenesis and Genomics Society (EMGS)Environmental Mutagen Society of India (EMS India)Iranian Environmental Mutagen Society (IrEMS)The Japanese Environmental Mutagen Society (JEMS)Korean Environmental Mutagen Society (KEMS)Molecular and Experimental Pathology Society of Australasia (MEPSA)Pan-African Environmental Mutagen Society (PAEMS)Philippines Environmental Mutagen Society (PEMS)Thai Environmental Mutagen Society (TEMS)Other Mutation Research sections: DNA Repair Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis (MR) Mutation Research - Reviews (MRR)
    Subscriptions

  • Cellular Signalling

    • ISSN: 0898-6568
    Cellular Signalling publishes original research describing fundamental and clinical findings on the mechanisms, actions and structural components of cellular signalling systems in vitro and in vivo.Cellular Signalling aims at full length research papers defining signalling systems ranging from microorganisms to cells, tissues and higher organisms.Cellular Signalling strives to offer a fair and fast peer-review process with a single round of revisions. Reviews are by invitation-only. Short Reports are not accepted.
    Subscriptions

  • Advances in Biological Regulation

    • ISSN: 2212-4926
    Advances in Biological Regulation (formerly Advances in Enzyme Regulation) reports cutting edge scientific progress on regulation at the molecular level, covering:The molecular biology of control of gene expression by hormones, drugs and growth factors in cancer cells and in clinical situations of metabolic diseases, inborn errors of metabolism and neoplasia.Stem cell biology and regenerative medicine issuesRegulatory networks, mainly in cellular signalling, differentiation, cell cycle & growth control, structure-function relationships, cell fate and lineage commitment or assembly mechanisms in cellsViruses, or supramolecular constructs, and signaling mechanisms mediating transcriptionGenomic... proteomic, bioinformatics and systems biology approaches to identify and characterize steps of biological control in cells.Complex cellular, pathogenic, clinical, or animal model systems studied by biochemical, molecular, genetic, epigenetic or quantitative ultrastructural approaches
    Subscriptions

  • Biochimica et Biophysica Acta: Reviews on Cancer

    • ISSN: 0304-419X
    BBA Reviews on Cancer covers the whole field of the biology and biochemistry of cancer, emphasizing oncogenes and tumor suppressor genes, growth-related cell cycle control signalling, carcinogenesis mechanisms, cell transformation, immunologic control mechanisms, genetics of human (mammalian) cancer, control of cell proliferation, genetic and molecular control of organismic development, rational anti-tumor drug design. In short, the journal presents critical invited reviews on new developments in cancer investigation at the molecular level.Types of papers published: mini-reviews, full reviews.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center
    Subscriptions

  • Biochimica et Biophysica Acta: Molecular Basis of Disease

    • ISSN: 0925-4439
    BBA Molecular Basis of Disease addresses the biochemistry and molecular genetics of disease processes and models of human disease.Manuscripts should emphasize the underlying molecular mechanisms of human disease pathways and provide significant advances to the understanding and/or treatment of these disorders.Studies in model organisms or systems are strongly recommended in order to validate mechanistic insights. Topics of interest include, but are not limited toAgingCancerCardiov... diseasesCell death–related diseasesGenetic diseasesGenetic and epigenetic regulation in diseasesImmunologica... diseasesInflammatory diseasesMetabolic diseasesMitochondria... diseasesMuscular diseasesNeurological diseasesThe non-preferred topics for BBADIS includeNon-coding RNAsResearch on non-coding RNAs (microRNAs, lncRNAs, circRNAs, etc.) will be considered only if it provides significantly novel insights into disease mechanisms.Single Cell Line StudiesStudies involving single cell lines will be considered only if they present significantly novel findings.Computation... (in Silico) StudiesPurely computational works (e.g., Mendelian randomization, molecular docking, molecular dynamics) will generally be declined unless they provide novel insights into disease mechanisms.Disease BiomarkersResearch on disease biomarkers will be considered only if it relates to the explanation of disease mechanisms.Descripti... or Correlative StudiesDescriptive or correlative studies (e.g., up/down regulation of gene products, -omics studies without follow-up experiments) will be declined unless they provide mechanistic insights.Natural Products and Traditional MedicineWork on natural products, extracts, and traditional medicine will be considered only if single biochemical components are characterized and tested.Clinical Studies and Case ReportsClinical studies or case reports without mechanistic insights are outside the scope of the journal.Hypothesis ArticlesSubmissions based solely on hypotheses will not be considered.Comparati... Genomics StudiesComparative genomics studies (e.g., GWAS) will only be considered if they provide specific insights into the structural and/or functional properties of individual genes.Incremental WorkResearch that offers incremental advancements without significant novelty or impact will generally be declined.
    Subscriptions

  • Drug Resistance Updates

    • ISSN: 1368-7646
    Drug Resistance Updates publishes inspiring original research, commentary and expert reviews on important developments in drug resistance in infectious disease and cancer as well as novel drugs and strategies to overcome drug resistance. It covers both basic research and clinical aspects of drug resistance, and involves disciplines as diverse as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology, and clinical medicine. The Editors welcome and encourage the submission of original research articles while review articles are written by leaders in the field of drug resistance by invitation.
    Subscriptions

  • Cancer Genetics

    • ISSN: 2210-7762
    The aim of Cancer Genetics is to publish high quality scientific papers on the cellular, genetic and molecular aspects of cancer, including cancer predisposition and clinical diagnostic applications. Specific areas of interest include descriptions of new chromosomal, molecular or epigenetic alterations in benign and malignant diseases; novel laboratory approaches for identification and characterization of chromosomal rearrangements or genomic alterations in cancer cells; correlation of genetic changes with pathology and clinical presentation; and the molecular genetics of cancer predisposition. To reach a basic science and clinical multidisciplinary audience, we welcome original full-length articles, reviews, meeting summaries, brief reports, and letters to the editor.Cancer Genetics is proud to be affiliated with the Cancer Genomics Consortium.
    Subscriptions

  • International Journal of Gynecological Cancer

    • ISSN: 1048-891X
    The International Journal of Gynecological Cancer (IJGC) serves as the primary educational and informational publication on topics related to the detection, prevention, diagnosis, and treatment of gynecologic malignancies.The content is intended for gynecologists, medical oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a special interest in gynecological oncology.IJGC promotes a multidisciplinary approach and features original research, reviews, and video articles.IJGC is the official journal of the European Society of Gynaecological Oncology (ESGO) and the International Gynecologic Cancer Society (IGCS).
    Subscriptions

  • Clinical Breast Cancer

    • ISSN: 1526-8209
    Clinical Breast Cancer is a peer-reviewed journal dedicated to publishing original articles on all aspects of clinical and translational research related to breast cancer. The journal focuses on the latest scientific advancements in the detection, diagnosis, prevention, and treatment of breast cancer.Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.Manuscrip... reporting non-clinical or translational studies must include functional experiments that directly support the study’s conclusions. Purely correlative studies without functional validation or mechanistic insights will not be considered. All research should demonstrate a clear and direct relevance to the clinical setting, highlighting potential implications for patient care or therapeutic development.
    Subscriptions

  • Clinical Lung Cancer

    • ISSN: 1525-7304
    Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
    Subscriptions

  • HPB

    • ISSN: 1365-182X
    To visit the HPB journal website click here: http://www.hpbonline... is an international forum for clinical, scientific and educational communication.Twelve issues a year bring the reader leading articles, expert reviews, original articles, images, editorials, and reader correspondence encompassing all aspects of benign and malignant hepatobiliary disease and its management. HPB features relevant aspects of clinical and translational research and practice.Specific areas of interest include HPB diseases encountered globally by clinical practitioners in this specialist field of gastrointestinal surgery. The journal addresses the challenges faced in the management of cancer involving the liver, biliary system and pancreas. While surgical oncology represents a large part of HPB practice, submission of manuscripts relating to liver and pancreas transplantation, the treatment of benign conditions such as acute and chronic pancreatitis, and those relating to hepatobiliary infection and inflammation are also welcomed. There will be a focus on developing a multidisciplinary approach to diagnosis and treatment with endoscopic and laparoscopic approaches, radiological interventions and surgical techniques being strongly represented. HPB welcomes submission of manuscripts in all these areas and in scientific focused research that has clear clinical relevance to HPB surgical practice.HPB aims to help its readers - surgeons, physicians, radiologists and basic scientists - to develop their knowledge and practice. HPB will be of interest to specialists involved in the management of hepatobiliary and pancreatic disease however will also inform those working in related fields.HPB is owned by the International Hepato-Pancreato-Bil... Association (IHPBA) and is also the official Journal of the American Hepato-Pancreato-Bil... Association (AHPBA), the Asian-Pacific Hepato Pancreatic Biliary Association (A-PHPBA) and the European-African Hepato-Pancreatic Biliary Association (E-AHPBA).
    Subscriptions